bisy BIOS GmbH
Number of employees: 1
Investors: We are actively looking for an investor to finalize our developments and to enable larger production.
Main focus areas/active in:
- Bio-based Materials
- Engineering / Scale-up
- Enzyme Technologies & Bioprocesses
- Strain Development
- Synthetic Biology
Protein-based molecules provide unique physical and biochemical characteristics and are biodegradable. Our mission is to find solutions for the production of protein-based biomaterials. Recombinant DNA-technologies offer viable alternatives to proteins of human or animal origin and provide unlimited access to natural compounds that are poorly accessible by extraction from plants, fungal or viral sources. For protein production we use the methylotrophic yeast Pichia pastoris (Komagataella phaffii). The dramatic COVID-19 situation and the associated over 2 millions of deaths led to our first available product: SARS-CoV-2 antigens. Our yeast produced SARS-CoV-2 antigens find application in research, diagnostics or can even be tested as a vaccine. Our business model is based on:
- Proteins – The production of antigens.
- Projects – Fee for service projects to produce tailored proteins and strains for research and commercial use.
- Applications – The development of antibody tests and vaccines.
Which input provides your business model/core technology towards a bio-based economy?
Nature provides us with an inspiring wealth of proteins. Biopolymers have repetitive sequences, which give them special properties such as strength or elasticity. Others, such as transmembrane glycoproteins of viruses, may be used in diagnostics or as vaccines. Yet others can be applied as catalysts in drug design. Recombinant protein production allows us to create smart materials and catalysts.
Which market/clients do you address and which short-/long-term goals do you have?
Our goal is to enable rapid diagnostics and vaccine development, by providing a safe, ecological and sustainable source of proteins. We aim to apply our antigens in antibody tests for various infectious diseases. We target the recombinant proteins and diagnostics market, which were estimated to € 100 billion and € 40 billion in 2020. We have estimated our SOM to € 2 and 200 million, respectively.
What makes your approach unique compared to other stakeholders in this field?
Our main USP is the cost-efficient production of high-quality proteins in the yeast Pichia pastoris. P. pastoris is an efficient alternative for recombinant protein production combining the simplicity of bacterial expression systems with some essential features of higher eukaryotic hosts. Innovative expression technology for gene expression enables us to produce high-quality biomaterials.
Get in touch!
Please fill out the form below to get in touch with us.